Press Releases Valerio Therapeutics London S.E.

Equities

0NWK

FR0010095596

Market Closed - London S.E. Other stock markets 04:48:08 30/11/2020 pm IST			5-day change	1st Jan Change
0.7551 ^EUR	-0.52%		+514.40%	+335.72%

22/05	Valerio Therapeutics S.A. Provides Clinical Development Update on Its Phase 1/2 VIO-01 Clinical Trial	CI
30/04	Valerio Therapeutics Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Valerio Therapeutics : Reports Full Year 2023 Financial Results and Provides Clinical Development Updates	24/05	PU
Valerio Therapeutics Provides Clinical Development Update on Its Phase 1/2 VIO-01 Clinical Trial	23/05	BU
Valerio Therapeutics : Publication of the 2023 Annual Report	23/05	PU
Valerio Therapeutics : Onxeo Receives Notice of Allowance from USPTO for New Patent Strengthening Protection of AsiDNA™ via Systemic Administration in the United States	13/05	PU
Valerio Therapeutics : Onxeo Announces the Transfer of the Listing of its Shares to Euronext Growth Paris on December 15, 2020	13/05	PU
Valerio Therapeutics : Annual financial and audit reports / Terms of availability of the annual financial report	01/05	PU
Valerio Therapeutics Reports Full Year 2023 Financial Results and Provides Clinical Development Updates	01/05	BU
Valerio Therapeutics : Reports Full Year 2023 Financial Results and Provides Clinical Development Updates	01/05	PU
Valerio Therapeutics : Publication of the 2023 Annual Report	01/05	PU
Onxeo : changes its name and becomes Valerio Therapeutics following approval by the Annual General Meeting of June 6, 2023	06/23/06	PU
Onxeo: Publication of the 2022 Annual Financial Report	29/23/29	BU
Onxeo Reports Full Year 2022 Financial Results and Provides Clinical Development Updates	24/23/24	BU
Onxeo will publish its full-year results on April 24, 2023	22/23/22	BU
Onxeo : Terms of availability of the preparatory documents for the GM	19/23/19	PU
Half-year liquidity contract statement for ONXEO	05/23/05	BU
Onxeo : Inside Information / News release on accounts, results	14/22/14	PU
Onxeo Reports its Half-Year 2022 Financial Results and Provides an Update on its Activities	14/22/14	BU
High-Grade Glioma Relapse in Children: Onxeo Announces the Enrollment of the First Patient in the Phase 1b/2 Clinical Study Conducted by the European ITCC Consortium and Sponsored by Institut Curie	01/22/01	BU
Onxeo Announces That Nasdaq Approved the Delisting of Its Shares From the First North Growth Market in Copenhagen	30/22/30	BU
Combined General Meeting of August 17, 2022: Onxeo Shareholders Approve Withdrawal From the Nasdaq First North Market in Copenhagen	17/22/17	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Valerio Therapeutics London S.E.

Equities

0NWK

FR0010095596

Press Releases

Filters